Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis

The Lancet Respiratory Medicine

Volumn 4, Issue 8, 2016, Pages 617-626

  Elborn, J Stuart ^a   Ramsey, Bonnie W ^b   Boyle, Michael P ^c   Konstan, Michael W ^d   Huang, Xiaohong ^e   Marigowda, Gautham ^e   Waltz, David ^e   Wainwright, Claire E ^f  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c DEPARTMENT OF PATHOLOGY   (United States)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

^e VERTEX PHARMACEUTICALS   (United States)

^f UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; CREATININE; DORNASE ALFA; IVACAFTOR PLUS LUMACAFTOR; PLACEBO; SODIUM CHLORIDE; 1,3 BENZODIOXOLE DERIVATIVE; AMINOPHENOL DERIVATIVE; AMINOPYRIDINE DERIVATIVE; CHLORIDE CHANNEL STIMULATING AGENT; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR DELTA F508; IVACAFTOR; LUMACAFTOR; QUINOLONE DERIVATIVE;

ADOLESCENT; ADULT; ARTICLE; BODY MASS; BREATHING; CFTR GENE; CHILD; CONTROLLED STUDY; COUGHING; CREATINE KINASE BLOOD LEVEL; CYSTIC FIBROSIS; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEMALE; FEVER; FORCED EXPIRATORY VOLUME; GENE; GENE MUTATION; GOOD CLINICAL PRACTICE; HEADACHE; HEMOPTYSIS; HOMOZYGOSITY; HOSPITAL ADMISSION; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; NAUSEA; NOSE OBSTRUCTION; OROPHARYNX PAIN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SPUTUM; UPPER RESPIRATORY TRACT INFECTION; VIRAL UPPER RESPIRATORY TRACT INFECTION; COMBINATION DRUG THERAPY; GENETICS; HOMOZYGOTE; LUNG; LUNG FUNCTION TEST; META ANALYSIS; MIDDLE AGED; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AMINOPHENOLS; AMINOPYRIDINES; BENZODIOXOLES; CHILD; CHLORIDE CHANNEL AGONISTS; CLINICAL TRIALS, PHASE III AS TOPIC; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FORCED EXPIRATORY VOLUME; HOMOZYGOTE; HUMANS; LUNG; MALE; MIDDLE AGED; QUINOLONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESPIRATORY FUNCTION TESTS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84994726301     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(16)30121-7     Document Type: Article

References (13)

1. 1 Bosch, B, De Boeck, K, Searching for a cure for cystic fibrosis. A 25-year quest in a nutshell. Eur J Pediatr 175 (2016), 1–8.
2. 2 O'Sullivan, BP, Freedman, SD, Cystic fibrosis. Lancet 373 (2009), 1891–1904.
3. 3 Cystic Fibrosis Foundation. Cystic Fibrosis Foundation Patient Registry 2013 Annual Data Report, 2014, Cystic Fibrosis Foundation, Bethesda, MD.
4. 4 Cai, ZW, Liu, J, Li, HY, Sheppard, DN, Targeting F508del-CFTR to develop rational new therapies for cystic fibrosis. Acta Pharmacol Sin 32 (2011), 693–701.
5. 5 Van Goor, F, Hadida, S, Grootenhuis, PD, et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc Natl Acad Sci USA 108 (2011), 18843–18848.
6. 6 Van Goor, F, Hadida, S, Grootenhuis, PD, et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci USA 106 (2009), 18825–18830.
7. 7 Flume, PA, Liou, TG, Borowitz, DS, et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation. Chest 142 (2012), 718–724.
8. 8 Clancy, JP, Rowe, SM, Accurso, FJ, et al. Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax 67 (2012), 12–18.
9. 9 Boyle, MP, Bell, SC, Konstan, MW, et al. A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. Lancet Respir Med 2 (2014), 527–538.
10. 10 Wainwright, CE, Elborn, JS, Ramsey, BW, et al. Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med 373 (2015), 220–231.
11. 11 Goss, CH, Burns, JL, Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis. Thorax 62 (2007), 360–367.
12. 12 Steinkamp, G, Wiedemann, B, on behalf of the German CFQA Group. Relationship between nutritional status and lung function in cystic fibrosis: cross sectional and longitudinal analyses from the German CF quality assurance (CFQA) project. Thorax 57 (2002), 596–601.
13. 13 Quittner, AL, Modi, AC, Wainright, C, et al. Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest 135 (2009), 1610–1618.